Hubert Grießner

Hubert Grießner serves as a physician-scientist at the Department of Urology and Andrology within the School of Medicine at Paracelsus Medical University, Salzburg. His clinical work spans both the University Clinic for Urology and Andrology and the University Clinic for Ear, Nose and Throat Diseases, with primary focus on urologic oncology and pharmacological interventions.

His research concentrates on advanced prostate cancer therapeutics, particularly androgen deprivation strategies, chemotherapy agents (docetaxel), and novel pharmacological compounds including darolutamide and abiraterone. Key methodological approaches encompass prospective randomized trials, real-world evidence analysis, and nuclear medicine applications for treatment response prediction.

Publication trends reveal consistent contributions to high-impact urologic oncology literature, with recent emphasis on triplet therapy protocols for metastatic disease, surgical technique comparisons for prostate conditions, and biomarker-driven treatment personalization using PSMA-targeted imaging. His collaborative Austrian multicenter studies demonstrate strong regional research integration.

Professional activities include academic presentations such as his 2019 opening lecture on urolithiasis, reflecting engagement in broader urological discourse beyond his primary oncology focus. His clinical-pharmacological expertise is evidenced through publications addressing both therapeutic innovations and infectious disease management within urological contexts.